Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 12 Sept 2023 |
| Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference | 28 Aug 2023 |
| Genmab A/S has published its Articles of Association | 16 Aug 2023 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 15 Aug 2023 |
| Genmab Announces Financial Results for the First Half of 2023 | 3 Aug 2023 |